 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company.
It develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.
In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder.
Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally.
Shares have formed a bullish "double bottom" following its latest quarterly report in February. It reported 4th Quarter December 2018 earnings of $2.17 per share on revenue of $1.1 billion. The consensus earnings estimate was $1.82 per share on revenue of $1.1 billion. The Earnings Whisper number was $1.95 per share. Revenue grew 24.1% on a year-over-year basis.
The company said it expects 2019 non-GAAP earnings of $9.10 to $9.30 per share on revenue of $4.625 billion to $4.70 billion. The current consensus earnings estimate is $8.73 per share on revenue of $4.76 billion for the year ending December 31, 2019. Higher share prices are expeted for this stock.
Entry Point: $134.00
Stop Loss: $128.00
Trading Range: $92.56 - $140.77
Target Price: $147.40
ALXN closed at $116.24
